



(51) International Patent Classification:

A61K 31/335 (2006.01) A61K 31/445 (2006.01)
A61K 31/495 (2006.01) A61K 31/33 (2006.01)
A61K 31/496 (2006.01)

(21) International Application Number:

PCT/US2024/025468

(22) International Filing Date:

19 April 2024 (19.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/460,764 20 April 2023 (20.04.2023) US
PCT/US2023/031835
01 September 2023 (01.09.2023) US
63/561,294 04 March 2024 (04.03.2024) US
63/575,594 05 April 2024 (05.04.2024) US

(71) Applicant: **AURON THERAPEUTICS, INC.** [US/US];
55 Chapel Street, Suite 102, Newton, Massachusetts 02458
(US).

(72) Inventors: **NEEF, James Anthony**; c/o Auron Therapeu-
tics, Inc., 55 Chapel Street, Suite 102, Newton, Massa-
chusetts 02458 (US). **MILLAN, David Simon**; c/o Auron

Therapeutics, Inc., 55 Chapel Street, Suite 102, Newton,
Massachusetts 02458 (US). **MCRINER, Andrew John**;
c/o Auron Therapeutics, Inc., 55 Chapel Street, Suite
102, Newton, Massachusetts 02458 (US). **AXFORD, Jake
Charles**; c/o Auron Therapeutics, Inc., 55 Chapel Street,
Suite 102, Newton, Massachusetts 02458 (US).


(74) Agent: **BERTINO, Lauren E.** et al.; CHOATE, HALL &
STEWART LLP, Two International Place, Boston, Massa-
chusetts 02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: TECHNOLOGIES TARGETING CELL STATES

(57) Abstract: Among other things, the present disclosure pro-
vides technologies targeting KAT2. In some embodiments, the
present disclosure provides technologies for reducing levels of
KAT2 polypeptides in various systems. In some embodiments,
the present disclosure provides technologies for treating vari-
ous diseases, disorders, or conditions, including those associat-
ed, with a KATZ polypeptide such as various cancers.



(A)




Figure 1
(CONTINUED)

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*